# A031701 (NCT03609216)

> Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03609216
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Alliance for Clinical Trials in Oncology
- Conditions: Infiltrating Bladder Urothelial Carcinoma; Stage II Bladder Urothelial Carcinoma; Stage III Bladder Urothelial Carcinoma
- Interventions: Gemcitabine Hydrochloride; Cisplatin; Pegfilgrastim; Conventional Surgery; Radical Cystectomy; Chemoradiotherapy
- Enrollment: 237
- Primary outcome: Proportion of patients who are recurrence-free within the DDR mutated group who undergo the bladder sparing approach

## Indexed commentary on A031701 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 5

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=a031701-nct03609216